12:00 AM
 | 
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Telatinib: Additional Phase II data

An analysis of serum samples from 28 evaluable patients in the open-label, U.S. and Spanish Phase II TEL0805 trial showed that both PFS and OS were significantly longer in patients who had a >=33% reduction in serum levels of the soluble form of the VEGF receptor 2 ( KDR/Flk-1; VEGFR-2) biomarker following treatment with twice-daily oral telatinib plus capecitabine and cisplatin. Specifically, patients with a greater reduction in soluble VEGFR-2...

Read the full 342 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >